Medical News

RSS

Researchers probe origin of optimized antibodies against infections

An organism's ability to make new antibodies and use them to optimize its own immune defenses is of central importance in the fight against pathogens. In the case of severe infections, the overall relative speed with which an immune response proceeds could mean the difference between life and death.

29 Jun 2012

Millennium introduces novel pharmacogenetic testing

Millennium Laboratories, the leading research-based clinical diagnostic company dedicated to improving the lives of people suffering from pain, announced today the introduction of Millennium Pharmacogenetic Testing.

29 Jun 2012

Bayer receives priority review designation from FDA for regorafenib NDA

Bayer HealthCare and Onyx Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted priority review designation to Bayer HealthCare's New Drug Application (NDA) filed end of April 2012 for the oral multi-kinase inhibitor regorafenib, for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed after approved standard therapies.

29 Jun 2012

Results from Access’ MuGard Phase 4 trial on oral mucositis

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company developing treatments in areas of oncology and oncology supportive care, announced that Dr. Ron R. Allison of Carolina Radiation Medicine, Greenville, NC, presented results from its ongoing MuGard Phase 4 clinical trial in oral mucositis (OM) at the Multinational Association of Supportive Care in Cancer (MASCC) Conference in New York City.

29 Jun 2012

Researchers create first animal model for RA

Researchers at Northwestern University Feinberg School of Medicine have created the first animal model that spontaneously develops rheumatoid arthritis (RA) and is predisposed towards atherosclerosis, or hardening of the arteries.

29 Jun 2012

Unilife prices underwritten offering of 6,154,000 shares of common stock

Unilife Corporation today announced the pricing of its underwritten offering of 6,154,000 shares of common stock at a price of $3.25 per share.

29 Jun 2012

Scientists discover new gene in the influenza virus

Scientists have discovered a new gene in the influenza virus that helps the virus control the body's response to infection.

29 Jun 2012

Social interactions during adolescence can affect health many years into adulthood

Social interactions during adolescence can affect health many years into adulthood, according to research published in the open access journal PLoS ONE.

29 Jun 2012

FSS’ FlexStent Iliac system receives CE Mark

Flexible Stenting Solutions, Inc., a leading developer of next generation peripheral arterial, venous, neurovascular and biliary stents, announced today that it has extended its CE Mark authorized family of peripheral vascular stents to include the FlexStent Iliac Self Expanding Stent System.

29 Jun 2012

Four organizations create University of Iowa Health Alliance

Four of Iowa's premier health care organizations announced today they are creating a health care alliance in Iowa and contiguous areas. The announcement was made in a statewide press conference, held today in several cities simultaneously.

29 Jun 2012

Gilead submits cobicistat NDA with FDA for treatment of HIV

Gilead Sciences, Inc. announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of cobicistat, a pharmacoenhancing or "boosting" agent that increases blood levels of certain commercially available protease inhibitors, including atazanavir and darunavir, in order to enable once-daily dosing.

29 Jun 2012

Researchers create 'Huntington's disease in a dish' to enable search for treatment

Johns Hopkins researchers, working with an international consortium, say they have generated stem cells from skin cells from a person with a severe, early-onset form of Huntington's disease (HD), and turned them into neurons that degenerate just like those affected by the fatal inherited disorder.

29 Jun 2012

Congressman 'dissatisfied' with handling of controversial H5N1 papers calls for cohesive policy for handling 'risky' research

"Dissatisfied with the government's handling of two research papers on mutant forms of avian influenza," Rep. Jim Sensenbrenner (R-Wisc.) on Wednesday "said that the lack of a cohesive policy for handling risky research funded by the National Institutes of Health (NIH) and other federal agencies could necessitate new laws, a situation that researchers have been trying to avoid," the Nature News Blog reports.

29 Jun 2012